2 weeks Ago By ABMN Staff
Rhumbline Advisers grew its position in shares of Ascendis Pharma A/S ( NASDAQ:ASND – Free Report ) by 10.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,533 shares of the biotechnology company’s stock after acquiring an additional 143 shares during the quarter.
Rhumbline Advisers’ holdings in Ascendis Pharma A/S were worth $209,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Other hedge funds have also recently bought and sold shares of the company. Vestal Point Capital LP bought a new position in shares of Ascendis Pharma A/S in the fourth quarter valued at approximately $78,719,000.
GSA Capital Partners LLP purchased a new position in Ascendis Pharma A/S in the first quarter worth $992,000. Price T Rowe Associates Inc. MD grew its stake in Ascendis Pharma A/S by 23.
3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after purchasing an additional 336,976 shares during the period.
ADAR1 Capital Management LLC bought a new position in Ascendis Pharma A/S in the 4th quarter valued at $5,779,000. Finally, Perceptive Advisors LLC purchased a new stake in shares of Ascendis Pharma A/S during the 4th quarter valued at $16,648,000. Wall Street Analysts Forecast Growth Several analysts have issued reports on the company.
Evercore ISI boosted their target price on Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a research note on Tuesday, September 17th.
Oppenheimer reiterated an “outperform” rating and set a $190.00 price objective (up from $180.00) on shares of Ascendis Pharma A/S in a research report on Tuesday, September 17th.
Citigroup increased their target price on Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a report on Tuesday, September 17th.
Cantor Fitzgerald reiterated an “overweight” rating and issued a $170.00 price objective on shares of Ascendis Pharma A/S in a report on Monday, September 16th. Finally, JPMorgan Chase & Co.
dropped their price objective on Ascendis Pharma A/S from $174.00 to $165.00 and set an “overweight” rating for the company in a report on Wednesday, September 4th.
Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $195.00.
Ascendis Pharma A/S Trading Down 1.9 % Ascendis Pharma A/S stock opened at $144.62 on Friday.
The firm has a market cap of $8.42 billion, a price-to-earnings ratio of -15.05 and a beta of 0.
63. The stock has a fifty day simple moving average of $134.39 and a two-hundred day simple moving average of $136.
48. Ascendis Pharma A/S has a 12 month low of $85.29 and a 12 month high of $161.
00. Ascendis Pharma A/S ( NASDAQ:ASND – Get Free Report ) last posted its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.
05) EPS for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51).
The business had revenue of $38.75 million during the quarter, compared to the consensus estimate of $94.74 million.
Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 154.18%.
On average, equities research analysts forecast that Ascendis Pharma A/S will post -7.15 EPS for the current fiscal year. Ascendis Pharma A/S Profile ( Free Report ) Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs.
It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. Read More Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Ascendis Pharma A/S ( NASDAQ:ASND – Free Report ). Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter .
.
